Literature DB >> 12951330

Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis.

I Lutsar1, I R Friedland, H S Jafri, L Wubbel, A Ahmed, M Trujillo, C C McCoig, G H McCracken.   

Abstract

Dexamethasone (DXM) interferes with the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and can thereby diminish the secondary inflammatory response that follows initiation of antibacterial therapy. A beneficial effect on the outcome of Haemophilus meningitis in children has been proven, but until recently the effect of DXM therapy in pneumococcal meningitis was uncertain. The aim of the present study was to evaluate factors that might influence the modulatory effect of DXM on the antibiotic-induced inflammatory response in a rabbit model of pneumococcal meningitis. DXM (1 mg/kg) was given intravenously 30 min before or 1 h after administration of a pneumococcal cell wall extract, or the first dose of ampicillin. In meningitis induced by cell wall extract, DXM therapy prevented the increase in cerebrospinal fluid (CSF) leucocyte and lactate concentrations, but only if given 30 min before the cell wall extract. In meningitis caused by live organisms, initiation of ampicillin therapy resulted in an increase in CSF TNF-alpha and lactate concentrations only in animals with initial CSF bacterial concentrations > or =5.6 log10 cfu/mL. In those animals, DXM therapy prevented significant elevations in CSF TNF-alpha [median change -184 pg/mL, -114 pg/mL versus +683 pg/mL with DXM (30 min before or 1 h after ampicillin) versus controls (no DXM), respectively, P=0.02] and lactate concentrations [median change -10.6 mmol/L, -1.5 mmol/L versus +14.3 mmol/L with DXM (30 min before or 1 h after ampicillin) versus controls (no DXM), respectively, P=0.01]. These effects were independent of the timing of DXM administration. In this model of experimental pneumococcal meningitis, an antibiotic-induced secondary inflammatory response in the CSF was demonstrated only in animals with high initial CSF bacterial concentrations (> or =5.6 log10 cfu/mL). These effects were modulated by DXM therapy whether it was given 30 min before or 1 h after the first dose of ampicillin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951330     DOI: 10.1093/jac/dkg417

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Adjunctive Corticosteroids in Adults with Bacterial Meningitis.

Authors:  Diederik van de Beek; Jan de Gans
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Steroids in bacterial meningitis: yes.

Authors:  Felix Benninger; Israel Steiner
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

Review 4.  Dexamethasone in adults with community-acquired bacterial meningitis.

Authors:  Diederik van de Beek; Jan de Gans
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.

Authors:  Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

Review 6.  Corticosteroids for acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Peter McIntyre; Kameshwar Prasad; Diederik van de Beek
Journal:  Cochrane Database Syst Rev       Date:  2015-09-12

7.  Dexamethasone treatment in adults with pneumococcal meningitis: risk factors for death.

Authors:  M Weisfelt; D van de Beek; J de Gans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

8.  Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice.

Authors:  Jeffrey E Gotts; Olivier Bernard; Lauren Chun; Roxanne H Croze; James T Ross; Nicolas Nesseler; Xueling Wu; Jason Abbott; Xiaohui Fang; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

9.  Inhibition of the lipoxin A4 and resolvin D1 receptor impairs host response to acute lung injury caused by pneumococcal pneumonia in mice.

Authors:  Emily R Siegel; Roxanne H Croze; Xiaohui Fang; Michael A Matthay; Jeffrey E Gotts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-06       Impact factor: 6.011

10.  Intrathecal administration of high-titer cytomegalovirus immunoglobulin for cytomegalovirus meningitis.

Authors:  Shin-Ichiro Fujiwara; Kazuo Muroi; Raine Tatara; Ken Ohmine; Tomohiro Matsuyama; Masaki Mori; Tadashi Nagai; Keiya Ozawa
Journal:  Case Rep Hematol       Date:  2014-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.